Home
Conditions
Burkitt Lymphoma

Clinical trial condition

Burkitt Lymphoma

Explore clinical trials studying Burkitt Lymphoma. Study availability and eligibility vary by location and protocol.

695 public trials 115 recruiting studies

Refine in advanced search Browse all conditions

Burkitt Lymphoma trial results

Not Yet Recruiting

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

NCT07113496

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL), Blood Protein Disorders, Burkitt Lymphoma, +34 more
Locations: The First Affiliated Hospital with Nanjing Medical University Nanjing, Jiangsu, China

View Trial Details

Not Yet Recruiting

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

NCT07043218

Conditions: B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations: Shanghai Tongji Hospital Shanghai, Shanghai Municipality, China

View Trial Details

Not Yet Recruiting

The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies

NCT07020260

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +16 more
Locations: University Medical Center Utrecht Utrecht, Netherlands

Princess Máxima Center for pediatric oncology Utrecht, Netherlands

View Trial Details

Not Yet Recruiting

Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT

NCT06861348

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +19 more
Locations: The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China

View Trial Details

Not Yet Recruiting

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1

NCT06777264

Conditions: Acute Lymphoblastic Leukemia, B Cell ALL, Burkitt Lymphoma, +20 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia

NCT06559644

Conditions: B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +19 more
Locations: The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China

View Trial Details

Not Yet Recruiting

A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

NCT04595162

Conditions: B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations: Not specified

View Trial Details

Completed

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

NCT01134575

Conditions: Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +23 more
Locations: University of Texas MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

NCT05653271

Conditions: B-cell Lymphoma, Burkitt Lymphoma, DLBCL, +23 more
Locations: AdventHealth Orlando Orlando, Florida, United States

Emory University Atlanta, Georgia, United States

Indiana University Simon Comprehensive Cancer Center Indianapolis, Indiana, United States

Norton Cancer Institute Louisville, Kentucky, United States

View all 13 locations

View Trial Details

Completed

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

NCT02997761

Conditions: Adult B Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +16 more
Locations: USC/Norris Comprehensive Cancer Center Los Angeles, California, United States

University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View Trial Details

Burkitt Lymphoma

Burkitt Lymphoma trial results

Related conditions